

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the “**Effective Date**”) by and between

Mark COBBOLD, Yariv MAZOR, Saso CEMERSKI, Dominique LISIERO, Qun DU, Cristina BERGAMASCHI, Ying FU, Amber LEE and Sterling R PAYNE, all US citizens, Thomas CIUCCI, a French citizen, Hanzhi ZHANG and Xiuling LI, both Chinese citizens, all of ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“**Assignors**”); and

ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership under no. 2810992, with registered office address at 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“**Assignee**”)

WHEREAS

- A. Assignors have made certain inventions (the “**Inventions**”) in respect of which the patent applications identified in the attached Schedule have been filed (the “**Applications**”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.


NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


Mark CORBOLD
Date: 3/4/25

Thomas CIUCCI
Date: _____

Yariv MAZOR
Date: _____

Saso CEMERSKI
Date: _____

Dominique LISIERO
Date: _____

Hanzhi ZHANG
Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Mark COBBOLD

Date: _____



Thomas CIUCCI

Date: 11/6/25


Yariv MAZOR

Date: _____



Saso CEMERSKI

Date: 01/06/2025



Dominique LISIERO

Date: 1/16/2025

Hanzhi ZHANG

Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.


Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Mark COBBOLD

Date: _____

Thomas CIUCCI

Date: _____


Yariv MAZOR

Date: 01/15/2025

Saso CEMERSKI

Date: _____

Dominique LISIERO

Date: _____

Hanzhi ZHANG

Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Mark COBBOLD

Date: _____

Thomas CIUCCI

Date: _____

Yariv MAZOR


Date: _____

Saso CEMERSKI

Date: _____

Dominique LISIERO

Date: _____



Hanzhi ZHANG

Date: 1/14/2025



Qun DU

Date: 1/14/2025

Cristina BERGAMASCHI

Date: _____

Xiuling LI

Date: _____

Ying FU

Date: _____

Amber LEE

Date: _____

Sterling R PAYNE

Date: _____



Signed for and on behalf of

ASTRAZENECA PHARMACEUTICALS LP

Name: Patrick Scott Alban

Title: Authorised Signatory

Date 4/10/2025

Qun DU

Date: _____

Cristina BERGAMASCHI

Date: 01/26/25

Xiuling LI

Date: _____

Ying FU

Date: _____

Amber LEE

Date: _____

Sterling R PAYNE

Date: _____

Signed for and on behalf of
ASTRAZENECA PHARMACEUTICALS LP
Name:
Title: Authorised Signatory

Qun DU

Date: _____

Cristina BERGAMASCHI

Date: _____



Xiuling LI

Date: 01/14/2025


Ying FU

Date: _____



Amber LEE

Date: 1/16/2025



Sterling R PAYNE

Date: 01/14/2025

Signed for and on behalf of
ASTRAZENECA PHARMACEUTICALS LP

Name:

Title: Authorised Signatory

Date: _____

Docket No. TITAN-100

Qun DU


Date: _____

Cristina BERGAMASCHI

Date: _____

Xiuling LI

Date: _____



Ying FU

Date: 2025-3-28

Amber LEE

Date: _____

Sterling R PAYNE

Date: _____

Signed for and on behalf of
ASTRAZENECA PHARMACEUTICALS LP
Name:
Title: Authorised Signatory

Date _____

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the “**Effective Date**”) by and between

Christopher LLOYD, Jonathan SEAMAN, Tilbe CREIGH-PULATMEN, Vijay CHENNUPATI, Owen VICKERY, all UK citizens and Laure CASTAN, a French citizen, all of ASTRAZENECA UK LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“**Assignors**”); and

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under no. 3674842, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“**Assignee**”)

WHEREAS

- A. Assignors have made certain inventions (the “**Inventions**”) in respect of which the patent applications identified in the attached Schedule have been filed (the “**Applications**”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.


5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the courts of England and Wales.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Christopher LLOYD

Date: 21 JAN 2025



Jonathan SEAMAN

Date: 17 JAN 2025

Tilbe CREIGH-PULATMEN

Date: _____

Vijay CHENNUPATI

Date: _____

Owen VICKERY

Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the courts of England and Wales.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Christopher LLOYD

Date: _____

Jonathan SEAMAN

Date: _____



Tilbe CREIGH-PULATMEN

Date: 20/01/2025

Vijay CHENNUPATI

Date: _____

Owen VICKERY

Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the courts of England and Wales.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Christopher LLOYD

Date: _____

Jonathan SEAMAN

Date: _____

Tilbe CREIGH-PULATMEN

Date: _____



Vijay CHENNUPATI

Date: 21 Jan 2025

Owen VICKERY

Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the courts of England and Wales.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Christopher LLOYD

Date: _____

Jonathan SEAMAN


Date: _____

Tilbe CREIGH-PULATMEN

Date: _____

Vijay CHENNUPATI

Date: _____



Owen VICKERY

Date: 15/1/2025



Laure CASTAN

Date: 17/01/2025



Signed for and on behalf of
ASTRAZENECA UK LIMITED

Name: ANDREW COOK

Title: Authorised Signatory

Date 19-MARCH-2025

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the "Effective Date") by and between

Corinne CAYATTE, a French citizen, Gilad KAPLAN, an Israeli citizen, Abigail Bowsbey LARA and Even WALSENG, both US citizens, all of MEDIMMUNE, LLC, One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("Assignors"); and

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America ("Assignee")

WHEREAS

- A. Assignors have made certain inventions (the "Inventions") in respect of which the patent applications identified in the attached Schedule have been filed (the "Applications").
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the "Rights"), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.


Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


Corinne CAYATTE

Date: 01/16/25

Gilad KAPLAN

Date: _____


Abigail Bowsbey LARA

Date: 1/16/25

Even WALSENG

Date: _____


Signed for and on behalf of
MEDIMMUNE, LLC
Name: Patrick Scott Alban
Title: Authorised Signatory

Date: 4/10/2025

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Corinne CAYATTE

Date: _____



Gilad KAPLAN

Date: 28 Feb 2025

Abigail Bowlsbey LARA

Date: _____

Even WALSENG

Date: _____

Signed for and on behalf of
MEDIMMUNE, LLC

Name:

Title: Authorised Signatory

Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of the State of Delaware and the parties hereby submit to the exclusive jurisdiction of the Delaware courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Corinne CAYATTE


Date: _____

Gilad KAPLAN

Date: _____

Abigail Bowsbey LARA

Date: _____


Even WALSENG

Date: 1/14/2025

Signed for and on behalf of
MEDIMMUNE, LLC

Name:

Title: Authorised Signatory

Date: _____

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the “Effective Date”) by and between

Simon DOVEDI, Alan SANDERCOCK, Suzanne SITNIKOVA, all UK citizens, Isabelle SERMADIRAS, a French citizen, all of MEDIMMUNE LIMITED, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“Assignors”); and

MEDIMMUNE LIMITED, a company incorporated in England and Wales under no. 2451177, whose registered office is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“Assignee”)

WHEREAS

- A. Assignors have made certain inventions (the “Inventions”) in respect of which the patent applications identified in the attached Schedule have been filed (the “Applications”).
- B. Assignee wishes to secure the entire right, title and interest in and to the Inventions and to the Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignors, receipt of which is hereby acknowledged, the Assignors hereby confirm that they have assigned, and in so far as there may be any outstanding rights that have not been assigned to the Assignee do hereby assign, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the Inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignors warrant that the Rights are unencumbered. Assignors acknowledge that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignors waive any right of first refusal that they may have for acquiring such Rights.
2. Assignors each hereby agree with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignors each hereby agree with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Simon DOVEDI

Date: 23/01/2025

Alan SANDERCOCK

Date: _____


Suzanne SITNIKOVA

Date: 23/01/2025

Isabelle SERMADIRAS

Date: _____

Signed for and on behalf of
MEDIMMUNE LIMITED

Name:

Title: Authorised Signatory

Date: _____


4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Simon DOVEDI

Date: _____



Alan SANDERCOCK

Date: 20 Jan 2025

Suzanne SITNIKOVA

Date: _____

Isabelle SERMADIRAS

Date: _____

Signed for and on behalf of
MEDIMMUNE LIMITED

Name:

Title: Authorised Signatory

Date: _____

4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Simon DOVEDI


Date: _____

Alan SANDERCOCK

Date: _____

Suzanne SITNIKOVA

Date: _____



Isabelle SERMADIRAS

Date: 15.01.2025



Signed for and on behalf of
MEDIMMUNE LIMITED

Name: ANDREW COOK
Title: Authorised Signatory

Date: 19-MARCH-2025

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the “**Effective Date**”) by and between

ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership under no. 2810992, with registered office address at 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437, United States of America (“**Assignor**”); and

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under no. 3674842, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“**Assignee**”).

WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “**Applications**”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


Signed for and on behalf of
ASTRAZENECA PHARMACEUTICALS LP
Name: Patrick Scott Alban
Title: Authorised Signatory

Date 4/10/2025


Signed for and on behalf of
ASTRAZENECA UK LIMITED
Name: MARK NESS
Title: Authorised Signatory
Date 11 APRIL 2025

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the “**Effective Date**”) by and between

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under no. 3674842, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“**Assignor**”); and

ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482, with registered office address at SE-151 85 Södertälje, Sweden (“**Assignee**”).

WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s legal right, legal title and legal interest in and to the patent applications identified in the attached Schedule (the “**Applications**”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the courts of England and Wales.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
ASTRAZENECA UK LIMITED

Name: MARK NESS

Title: Authorised Signatory

Date 11 April 2025



Signed for and on behalf of
ASTRAZENECA AB

Name: ANDREW COOK

Title: Authorised Signatory

Date 23 APRIL 2025

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the “**Effective Date**”) by and between

MEDIMMUNE, LLC, a limited liability company formed under the laws of the State of Delaware under no. 2130616, whose post office address is One MedImmune Way, Gaithersburg, Maryland 20878, the United States of America (“**Assignor**”); and

ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482, with registered office address at SE-151 85 Södertälje, Sweden (“**Assignee**”).


WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “**Applications**”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:


1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.


Signed for and on behalf of
MEDIMMUNE, LLC
Name: Patrick Scott Alban
Title: Authorised Signatory

Date 4/10/2025


Signed for and on behalf of
ASTRAZENECA AB
Name: MARK NESS
Title: Authorised Signatory

Date 11 APRIL 2025

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the 9th October 2024 (the “**Effective Date**”) by and between

MEDIMMUNE LIMITED, a company incorporated in England and Wales under no. 2451177, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom (“**Assignor**”); and

ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482, with registered office address at SE-151 85 Södertälje, Sweden (“**Assignee**”).

WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “**Applications**”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely their entire right, title and interest in and to the inventions, the Applications and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Applications and any patents or applications derived therefrom; and the right to file patent applications derived from the Applications directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.

5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.



Signed for and on behalf of
MEDIMMUNE LIMITED

Name: MARK NESS

Title: Authorised Signatory

Date: 11 April 2025



Signed for and on behalf of
ASTRAZENECA AB

Name: ANDREW COOK

Title: Authorised Signatory

Date: 23 APRIL 2025

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-AR-NP	Argentina	National	P240102741	09 October 2024
TITAN-100-WO-PCT	International	PCT	PCT/EP2024/078335	09 October 2024
TITAN-100-PK-NP	Pakistan	National	711/2024	09 October 2024
TITAN-100-TW-NP	Taiwan	National	113138436	09 October 2024
TITAN-100-US-NP	USA	National	18/910,389	09 October 2024

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
TITAN-100-US-PSP	USA	Provisional	63/589,297	10 October 2023
TITAN-100-US-PSP[2]	USA	Provisional	63/658,583	11 June 2024